JP Morgan Reinstates Neutral on Legend Biotech, Announces $35 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 82.4%

Neg 0% Neu 82.4% Pos 0%

JP Morgan analyst Jessica Fye reinstates Legend Biotech (NASDAQ:LEGN) with a Neutral and announces $35 price target.

Comments

No comments yet. Be the first!